Jill Feldman is a lung cancer patient and advocate. With an extensive family history of lung cancer, Jill got involved in lung cancer advocacy in 2001, when it was in its infancy. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR-positive lung cancer.
Jill is committed to understanding and promoting patient-centered research as past Chair of IASLC’s patient advisory board, a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a member of the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee, and as the patient advocate on the National Lung Cancer Round Table steering committee. In addition, she is a co-founder of the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will pro-long and better the lives of people diagnosed with EGFRm lung cancer.
Jill serves in various other leadership roles to improve the speed and quality of research and use her voice and privilege to embed a health equity lens in all aspects of research and care. She is passionate about advocating for the critical aspects of the lived experience, including the physical, psychosocial, logistical, and financial effects of cancer and treatment on patients and families.
Disclosure information not submitted.
Lending Patient Experiences to Medical Education: More Than the Journey (Level 1)
Tuesday, February 6, 2024
3:45 PM – 4:15 PM CST